Nexstim (NXTMH) H2 2025 earnings summary

Executive summary

• Achieved 26% revenue growth in 2025, reaching €10.97M–€11.0M, outpacing the previous strategy period's 21% CAGR from 2020–2024.

• All profitability metrics turned positive, with net income at €0.6M, reversing a €0.9M loss from the prior year, and operating profit positive for the first time without significant adjustments.

• Strong commercial momentum driven by new partnerships and product launches, notably with Brainlab and Sinaptica.

• Expanded global presence, including strengthened position in the US, strong demand in the EU, and initial steps into Asia.

• Secured MDR certification for NBS 6 in EU and advanced regulatory approvals in both FDA and CE.

Financial highlights

• Revenue for 2025 reached €10.97M–€11.0M, up 25.6% year-over-year; gross margin at 77.1%.

• Adjusted EBITDA was €1.7M (16% margin), with operating profit at €637K–€0.6M, and net profit at €573K–€0.6M.

• Earnings per share improved to €0.08; diluted EPS: €0.06.

• Operating expenses grew only 1% to €8.2M, supporting scalable growth.

• Equity ratio improved to 39.7% from 31.2% in 2024.

Outlook and guidance

• Expects continued revenue growth and further improvement in operating profit for 2026.

• Long-term targets: maintain over 20% annual revenue growth and achieve over 20% operating margin.

• Strategic focus on profitable growth, minimizing future capital needs, and leveraging partnerships.